247 related articles for article (PubMed ID: 36822570)
21. [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment].
Wildemann B; Horstmann S; Korporal-Kuhnke M; Viehöver A; Jarius S
Klin Monbl Augenheilkd; 2020 Nov; 237(11):1290-1305. PubMed ID: 33202462
[TBL] [Abstract][Full Text] [Related]
22. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
[TBL] [Abstract][Full Text] [Related]
23. Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD.
Akaishi T; Himori N; Takeshita T; Misu T; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Fujihara K; Nakazawa T; Nakashima I
J Neurol Sci; 2022 Jun; 437():120269. PubMed ID: 35483239
[TBL] [Abstract][Full Text] [Related]
24. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
Hassan MB; Stern C; Flanagan EP; Pittock SJ; Kunchok A; Foster RC; Jitprapaikulsan J; Hodge DO; Bhatti MT; Chen JJ
Am J Ophthalmol; 2020 Dec; 220():110-114. PubMed ID: 32707199
[TBL] [Abstract][Full Text] [Related]
25. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
26. Optic neuritis in Turkish children and adolescents: A multicenter retrospective study.
Direk MÇ; Besen Ş; Öncel İ; Günbey C; Özdoğan O; Orgun LT; Sahin S; Cansu A; Yıldız N; Kanmaz S; Yılmaz S; Tekgül H; Türkdoğan D; Ünver O; Thomas GÖ; Başıbüyük S; Yılmaz D; Kurt AN; Gültutan P; Özsoy Ö; Yiş U; Kurul SH; Güngör S; Özgör B; Karadağ M; Dündar NO; Gençpınar P; Bildik O; Orak SA; Kabur ÇÇ; Kara B; Karaca Ö; Canpolat M; Gümüş H; Per H; Yılmaz Ü; Karaoğlu P; Ersoy Ö; Tosun A; Öztürk SB; Yüksel D; Atasoy E; Gücüyener K; Yıldırım M; Bektaş Ö; Çavuşoğlu D; Yarar Ç; Güngör O; Mert GG; Sarıgeçili E; Edizer S; Çetin İD; Aydın S; Diler B; Özdemir AA; Erol İ; Okuyaz Ç; Anlar B
Mult Scler Relat Disord; 2024 Jan; 81():105149. PubMed ID: 38096730
[TBL] [Abstract][Full Text] [Related]
27. The Treatment of Acute Optic Neuritis.
Keyhanian K; Chwalisz BK
Semin Ophthalmol; 2023 Aug; 38(6):511-514. PubMed ID: 37162276
[TBL] [Abstract][Full Text] [Related]
28. Clinical difference after the first optic neuritis between aquaporin-4-IgG-associated and myelin oligodendrocyte glycoprotein-IgG-associated disorders.
Masuda H; Mori M; Yokouchi H; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Yamamoto S; Kuwabara S
J Neurol; 2022 Apr; 269(4):1996-2003. PubMed ID: 34455476
[TBL] [Abstract][Full Text] [Related]
29. Evidence-based management of optic neuritis.
Bergeron E; Bouffard MA
Curr Opin Ophthalmol; 2024 Jan; 35(1):73-82. PubMed ID: 37846574
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Mult Scler Relat Disord; 2023 Apr; 72():104611. PubMed ID: 36907119
[TBL] [Abstract][Full Text] [Related]
31. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.
Songthammawat T; Srisupa-Olan T; Siritho S; Kittisares K; Jitprapaikulsan J; Sathukitchai C; Prayoonwiwat N
Mult Scler Relat Disord; 2020 Feb; 38():101506. PubMed ID: 31731214
[TBL] [Abstract][Full Text] [Related]
32. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
[No Abstract] [Full Text] [Related]
33. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
34. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
35. [Optic neuropathy in positive anti-MOG antibody syndrome].
Merabtene L; Vignal Clermont C; Deschamps R
J Fr Ophtalmol; 2019 Dec; 42(10):1100-1110. PubMed ID: 31732265
[TBL] [Abstract][Full Text] [Related]
36. [OPTIC NEURITIS - CLASSIFICATION, MANAGEMENT AND TREATMENT].
Almer Z
Harefuah; 2022 Oct; 161(10):645-651. PubMed ID: 36315205
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of plasma exchange for the treatment of optic neuritis in neuromyelitis optica spectrum disorders: A protocol for systematic review and meta-analysis.
Han M; Chen Y; Nong L; Liu Z; Hao L; Wang Z
Medicine (Baltimore); 2020 Jul; 99(28):e21067. PubMed ID: 32664124
[TBL] [Abstract][Full Text] [Related]
38. Clinical profile and challenges faced in the management of optic neuritis: the Indian scenario.
Kaushik M; Shah VM; Murugesan S; Mani KK; Vardharajan S
Int Ophthalmol; 2024 Mar; 44(1):138. PubMed ID: 38488890
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature.
Aungsumart S; Apiwattanakul M
Mult Scler Relat Disord; 2017 Apr; 13():93-97. PubMed ID: 28427710
[TBL] [Abstract][Full Text] [Related]
40. [Effects of intravenous methylprednisolone pulse therapy on optic neuritis associated with AQP4 antibody seropositive neuromyelitis optica].
Guo ST; Li Z; Jiang LB; Wu RH; Peng JT; Wang JW; Wei WB
Zhonghua Yan Ke Za Zhi; 2019 Mar; 55(3):180-185. PubMed ID: 30841684
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
